Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice
- Conditions
- Breast Neoplasms
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 46
- Registration Number
- NCT02655159
- Locations
- 🇪🇸
Complejo Hospitalario Jaén, Jaén, Andalucía, Spain
🇪🇸Hospital Clínico Lozano Blesa, Zaragoza, Aragón, Spain
🇪🇸Hospital Navarra, Pamplona, Navarra, Spain
A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- Celgene
- Target Recruit Count
- 310
- Registration Number
- NCT02641392
- Locations
- 🇦🇺
Liverpool Hospital, Liverpool, New South Wales, Australia
🇷🇸Military Medical Academy, Belgrade, Serbia
🇬🇧John Radcliffe Hospital, Oxford, United Kingdom
A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)
- Conditions
- Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 28
- Registration Number
- NCT02641002
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Mayo Clinic Phoenix, Phoenix, Arizona, United States
Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 17
- Registration Number
- NCT02635061
- Locations
- 🇺🇸
Local Institution - 350, Boston, Massachusetts, United States
A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Celgene
- Target Recruit Count
- 229
- Registration Number
- NCT02631070
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇩🇪Universitatsklinikum Bonn, Bonn, Germany
To Document the Burden of Illness on the Quality of Life and the Impact on Healthcare Utilization in (Beta) β-thalassemia Subjects Who Are Transfusion Dependent (TD) and Non-transfusion Dependent (NTD) Receiving Standard of Care
- Conditions
- Beta-Thalassemia
- Interventions
- Other: Quality of Life (QOL) questionnairesOther: Healthcare Resource Utilization
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 100
- Registration Number
- NCT02626689
- Locations
- 🇬🇷
Aghia Sofia Children's Hosptial, Athens, Goudi, Greece
🇮🇹Fondazione IRCCS Ca Granda Ospedale Maggiore, Milano, Italy
🇱🇧American University of Beirut Medical Center, Beirut, Lebanon
Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer
- Conditions
- Metastatic Pancreas Adenocarcinoma
- Interventions
- First Posted Date
- 2015-12-03
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 12
- Registration Number
- NCT02620800
- Locations
- 🇺🇸
Tufts - New England Medical Center, Boston, Massachusetts, United States
🇺🇸Gibbs Cancer Center and Research Institute, Spartanburg, South Carolina, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 114
- Registration Number
- NCT02616640
- Locations
- 🇺🇸
Local Institution - 108, Boston, Massachusetts, United States
🇺🇸Local Institution - 115, Boston, Massachusetts, United States
🇪🇸Local Institution - 504, Madrid, Spain
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia
- Conditions
- Erythrocyte TransfusionBeta-Thalassemia
- Interventions
- Other: Placebo
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 336
- Registration Number
- NCT02604433
- Locations
- 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇦🇺Royal Adelaide Hospital Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
🇬🇷Laiko General Hospital of Athens, Ampelokipi - Athens, Greece
An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis
- First Posted Date
- 2015-11-10
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Celgene
- Target Recruit Count
- 41
- Registration Number
- NCT02601300
- Locations
- 🇧🇬
Multiprofile Hospotal for Active Treatment- Sveti Nikolay Chudotvoretz - LOM EOOD, Lom, Bulgaria
🇸🇰Fakultna nemocnica s poliklinikou F. D. Roosevelta, Banska Bystrica, Slovakia
🇧🇬Multiprofile Hospital for Active Treatment Doverie AD, Sofia, Bulgaria